Physician profile
Jonathan Gray
NPI 1881047199
$458.29
in general payments reported to CMS, 2019-2025
14 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.85 · 2023: $104 · 2024: $186 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $398 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $398.44 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $92.07 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $70.96 | 2023-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $45.00 | 2025 | |
| Corcept Therapeutics | $38.83 | 2023-2025 | Korlym |
| Pfizer INC. | $31.87 | 2024 | |
| Itamar Medical INC | $30.57 | 2024 | Watchpatone |
| Xeris Pharmaceuticals, INC. | $30.21 | 2024 | Keveyis |
| Exact Sciences Corporation | $21.07 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $20.77 | 2024 | Trelegy Ellipta |
| Daiichi Sankyo INC. | $19.94 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $15.77 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.85 | 2022 | |
| Bausch Health US, LLC | $13.52 | 2024 | Wellbutrin, Aplenzin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.86 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.